Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617020 | 0.95 | TLR7 (0.41) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL5617070 | 0.91 | TLR7 (0.43) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL5616953 | 0.91 | TLR7 (0.41) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL1141273 | 0.90 | TLR7 (0.40) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL5616950 | 0.87 | TLR7 (0.41) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL1892074 | 0.85 | TLR7 (0.44) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL1141430 | 0.85 | TLR7 (0.41) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL5616924 | 0.85 | SMN1; SMN2 (0.38) | TLR7MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL5148465 | 0.84 | TLR7 (0.40) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL1141057 | 0.84 | TLR7 (0.42) | TLR7TLR8NUDT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697873-B2 | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| EP-1730143-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094531-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | TLR7 123/4885TLR8 150/4885NUDT1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.